JAGX vs. ACXP, NLSP, GLYC, CYCN, TLPH, ADXN, APRE, GTBP, DWTX, and KPRX
Should you be buying Jaguar Animal Health stock or one of its competitors? The main competitors of Jaguar Animal Health include Acurx Pharmaceuticals (ACXP), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), Cyclerion Therapeutics (CYCN), Talphera (TLPH), Addex Therapeutics (ADXN), Aprea Therapeutics (APRE), GT Biopharma (GTBP), Dogwood Therapeutics (DWTX), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.
Jaguar Animal Health vs. Its Competitors
Jaguar Animal Health (NASDAQ:JAGX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health.
Acurx Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -343.92%. Jaguar Animal Health's return on equity of -432.91% beat Acurx Pharmaceuticals' return on equity.
In the previous week, Jaguar Animal Health and Jaguar Animal Health both had 2 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.94 beat Jaguar Animal Health's score of 0.93 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Jaguar Animal Health has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.
Jaguar Animal Health currently has a consensus target price of $60.00, indicating a potential upside of 2,122.22%. Acurx Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 1,591.33%. Given Jaguar Animal Health's higher possible upside, equities analysts clearly believe Jaguar Animal Health is more favorable than Acurx Pharmaceuticals.
12.0% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 0.4% of Jaguar Animal Health shares are owned by company insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Jaguar Animal Health beats Acurx Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Get Jaguar Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:JAGX) was last updated on 7/12/2025 by MarketBeat.com Staff
